Fed’s Powell opens door to potential rate cuts at Jackson Hole
On Wednesday, Citi analyst Samantha Semenkow adjusted the price target for Voyager Therapeutics (NASDAQ:VYGR) shares, bringing it down to $11.00 from the previous $12.00. Currently trading at $3.97, near its 52-week low of $3.80, the stock remains significantly below its peak of $10.66. Despite the reduction, the firm continues to recommend a Buy rating for the biotechnology company’s stock, aligning with the broader analyst consensus. According to InvestingPro data, analyst price targets range from $9 to $30, suggesting substantial upside potential.
Voyager Therapeutics recently shared its single ascending dose (SAD) data for VY7523, an anti-Tau C-terminal antibody, which showed a clean safety profile. This update is part of the company’s ongoing efforts to develop treatments for Alzheimer’s disease. The initial multiple ascending dose (MAD) Tau-PET data for VY7523 in Alzheimer’s patients is expected to be released in the second half of 2026.
The company has reiterated its projection that multiple third-party readouts within the next 12 to 18 months will further validate the potential of Tau-targeted therapies for Alzheimer’s disease. During the upcoming ADPD™25 conference, scheduled for April 1-5, Voyager plans to present additional data on VY7523 and initial preclinical non-human primate data for VY1706, a Tau silencing gene therapy. Preliminary results have shown Tau mRNA knockdown ranging from 50-73%. The company is currently conducting IND-enabling studies for VY1706, with an IND filing anticipated for 2026.
Furthermore, Voyager is preparing to file IND applications for its gene therapy programs targeting Parkinson’s and Friedreich’s Ataxia, in partnership with Neurocrine (NASDAQ:NBIX), by 2025. The company also highlighted its ongoing discovery work on an ALPL-based non-viral shuttle, with the expectation of revealing initial pre-clinical data later this year.
In her report, Semenkow reiterated the Buy/High Risk rating and emphasized the new price target of $11.00 for Voyager Therapeutics shares.
In other recent news, Voyager Therapeutics reported its Q4 2024 earnings, revealing an earnings per share (EPS) of -0.37, which met analysts’ expectations. Although the EPS aligned with forecasts, the company did not disclose its revenue forecast, contributing to a notable 8.82% decline in after-hours trading. Despite this, Voyager maintains a strong cash position of $332 million and has potential future milestone payments totaling $8.2 billion. The company’s cash runway is projected to extend to mid-2027, supported by revenue from partnerships. Voyager’s advancements include its VY1706 tau silencing gene therapy, which has moved to IND-enabling studies, and the completion of a single ascending dose study for its VY7523 anti-tau antibody. Analysts, such as those from Baird and TD Cowen, have shown interest in the company’s pipeline and potential milestones. Voyager continues to explore partnership opportunities, which could further bolster its financial standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.